Equities research analysts predict that Natera, Inc. (NASDAQ:NTRA) will report ($1.28) earnings per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Natera’s earnings. The highest EPS estimate is ($1.23) and the lowest is ($1.35). Natera posted earnings of ($0.72) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 77.8%. The company is expected to announce its next earnings report on Thursday, November 4th.
On average, analysts expect that Natera will report full-year earnings of ($4.63) per share for the current year, with EPS estimates ranging from ($4.67) to ($4.59). For the next financial year, analysts forecast that the company will report earnings of ($4.20) per share, with EPS estimates ranging from ($4.76) to ($3.33). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Natera.
Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 5th. The medical research company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.05) by ($0.27). Natera had a negative net margin of 62.31% and a negative return on equity of 74.29%. The company had revenue of $142.03 million for the quarter, compared to analysts’ expectations of $140.50 million.
Shares of NASDAQ NTRA traded down $7.86 during midday trading on Thursday, hitting $107.26. 1,232,087 shares of the company’s stock traded hands, compared to its average volume of 937,188. The firm has a fifty day moving average of $114.92 and a 200 day moving average of $107.74. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of -31.37 and a beta of 1.26. Natera has a 1 year low of $65.61 and a 1 year high of $129.09. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.59 and a current ratio of 3.74.
In other news, CEO Steven Leonard Chapman sold 1,649 shares of the company’s stock in a transaction dated Thursday, September 23rd. The shares were sold at an average price of $125.67, for a total transaction of $207,229.83. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel Rabinowitz sold 446 shares of the stock in a transaction dated Thursday, September 23rd. The shares were sold at an average price of $125.67, for a total value of $56,048.82. The disclosure for this sale can be found here. Insiders have sold a total of 225,573 shares of company stock valued at $26,279,880 in the last three months. 10.86% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. bought a new position in Natera in the 1st quarter valued at $28,000. Advisory Services Network LLC bought a new position in Natera in the second quarter worth approximately $32,000. Tobam bought a new position in Natera during the first quarter valued at $38,000. Itau Unibanco Holding S.A. bought a new position in Natera in the 2nd quarter worth about $38,000. Finally, Berman Capital Advisors LLC lifted its position in Natera by 5,766.7% in the 2nd quarter. Berman Capital Advisors LLC now owns 352 shares of the medical research company’s stock worth $39,000 after buying an additional 346 shares during the last quarter. Institutional investors own 93.97% of the company’s stock.
Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).
Further Reading: Moving Average – How it Helps Investors in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.